Caption Management’s Larimar Therapeutics LRMR Stock Holding History

Caption Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Sell	193,018 -442,006	-70%	-$1.76M	﹤0.01%	1287
2026 Q1	$2.86M	Buy	635,024 +219,730	+53%	+$878K	0.02%	715
2025 Q4	$1.58M	Sell	415,294 -897,058	-68%	-$3.49M	0.01%	913
2025 Q3	$4.24M	Buy	1,312,352 +623,062	+90%	+$2.34M	0.03%	557
2025 Q2	$1.99M	Buy	+689,290	New	+$1.6M	0.02%	714
2024 Q2	–	Sell	-142,900	Closed	-$1.08M	–	1364
2024 Q1	$1.08M	Buy	+142,900	New	+$1.11M	0.02%	710

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Caption Management's LRMR Position: Q2 2026 in Review

Caption Management reduced its Larimar Therapeutics (LRMR) stake by 70% in Q2 2026, selling an estimated $1.76M and leaving 193,018 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #1287.

Caption Management first reported a position in LRMR in Q1 2024 and has held it in 6 quarters since. The position peaked at $4.24M in Q3 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Caption Management held 193,018 shares of Larimar Therapeutics worth $589K as of Q2 2026.
Caption Management sold 442,006 Larimar Therapeutics shares in Q2 2026, an estimated $1.76M.
Larimar Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1287 holding.
Caption Management first reported a position in Larimar Therapeutics in Q1 2024 and has held it in 6 quarters since.
Caption Management's Larimar Therapeutics position peaked at $4.24M in Q3 2025.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.